GSK plc vs Evotec SE: SG&A Expense Trends

SG&A Expense Trends: GSK plc vs Evotec SE

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Over the past decade, GSK plc and Evotec SE have demonstrated distinct approaches in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, GSK plc consistently maintained higher SG&A expenses, peaking in 2020 with a 39% increase from 2014. This reflects their expansive global operations and robust marketing strategies. In contrast, Evotec SE, a smaller player, showed a remarkable 843% increase in SG&A expenses over the same period, indicating aggressive growth and expansion efforts. Notably, 2022 marked a significant shift for both companies, with GSK's expenses dropping by 27% from the previous year, while Evotec continued its upward trajectory. These trends highlight the dynamic nature of financial management in the pharmaceutical sector, offering insights into each company's strategic priorities.